Researchers are exploring the use of CAR T-cell therapy to treat autoimmune diseases, with some studies targeting specific cells, such as B cells. This approach, which involves reprogramming immune cells, is showing early promise. The development of this therapy is also attracting investment from pharmaceutical companies, with several major players making significant financial bets on its potential.